摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Chloro-2-pyridin-4-yl-thieno[3,2-d]pyrimidine | 214417-24-0

中文名称
——
中文别名
——
英文名称
4-Chloro-2-pyridin-4-yl-thieno[3,2-d]pyrimidine
英文别名
4-chloro-2-pyridin-4-ylthieno[3,2-d]pyrimidine
4-Chloro-2-pyridin-4-yl-thieno[3,2-d]pyrimidine化学式
CAS
214417-24-0
化学式
C11H6ClN3S
mdl
——
分子量
247.708
InChiKey
KFXHPOCRGHJEIX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    326.554±42.00 °C(Press: 760.00 Torr)(predicted)
  • 密度:
    1.458±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    66.9
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    WO2008/92862
    摘要:
    公开号:
  • 作为产物:
    参考文献:
    名称:
    Design, Synthesis, and Biological Activities of New Thieno[3,2-d]pyrimidines as Selective Type 4 Phosphodiesterase Inhibitors
    摘要:
    A common pharmacophore for compounds structurally related to nitraquazone has been derived. Using this pharmacophore, new structures have been designed, synthesized, and evaluated for their inhibitory potencies against cyclic adenosine 5'-monophosphate (cAMP) specific phosphodiesterase (PDE 4). From these compounds, 4-benzylamino-2-butylthieno[3,2-d]-pyrimidine (4) was selected for optimization. The effects of changes to the lipophilic groups and the amino linkage on the PDE 4 activity have been investigated. As a result, some potent PDE 4 inhibitors, selective with respect to PDE 3, have been identified. A selected group of compounds have been further evaluated for their ability to displace [H-3]rolipram from its binding site and also to potentiate isoprenaline-induced cAMP accumulation in isolated guinea pig eosinophils. Of these, 2-butyl-4-cyclohexylaminothieno[3,2-d]pyrimidine (33) has an interesting profile, with an important improvement in PDE 4/[H-3]rolipram ratio with respect to reference drugs, and good activity in cAMP potentiation, consistent with efficient cell penetration.
    DOI:
    10.1021/jm981012m
点击查看最新优质反应信息

文献信息

  • [EN] THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C<br/>[FR] INHIBITEURS DE TYPE THIÉNOPYRIMIDINE DE PROTÉINES KINASES C ATYPIQUES
    申请人:CANCER REC TECH LTD
    公开号:WO2013078126A1
    公开(公告)日:2013-05-30
    The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.
    本发明提供了一种式(I)的化合物或其盐,其中R1、R2、R3、R4、R5、R6、A、G、M、Q和X如本文所定义。式(I)的化合物及其盐具有PKC抑制活性,并可用于治疗增生性疾病。
  • Thienopyrimidine Inhibitors of Atypical Protein Kinase C
    申请人:Cancer Research Technology Limited
    公开号:US20140323435A1
    公开(公告)日:2014-10-30
    The present application provides a compound of formula (I) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    本申请提供了公式(I)的化合物或其盐,其中R1、R2、R3、R4、R5、R6、A、G、M、Q和X的定义如本文所述。公式(I)的化合物及其盐具有aPKC抑制活性,可用于治疗增殖性疾病。
  • THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C
    申请人:Cancer Research Technology Limited
    公开号:EP3048106A1
    公开(公告)日:2016-07-27
    The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. The compound of formula (I) and its salts has aPKC inhibitory activity, and may be used to treat proliferative disorders.
    本发明提供了一种式 (I) 的化合物 或其盐,其中 R1、R2、R3、R4、R5、R6、A、G、M、Q 和 X 如本文所定义。式(I)化合物及其盐具有 PKC 抑制活性,可用于治疗增殖性疾病。
  • Thienopyrimidine inhibitors of atypical protein kinase C
    申请人:Cancer Research Technology Limited
    公开号:US10183950B2
    公开(公告)日:2019-01-22
    The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    本申请提供了一种式 (I) 的化合物 或其盐,其中 R1、R2、R3、R4、R5、R6、A、G、M、Q 和 X 如本文所定义。式(I)化合物及其盐具有 PKC 抑制活性,可用于治疗增殖性疾病。
  • EP2782917A1
    申请人:——
    公开号:EP2782917A1
    公开(公告)日:2014-10-01
查看更多